IP Library Patent Application 10961789
Patent Application
App. No. 10/961,789

Induction of immune response against desired determinants

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/961,789
Abstract

This invention provides HLA-DR binding peptides, called “pan DR binding peptides” that are recognized by a broad spectrum of DR molecules. In particular, the present invention provides compositions comprising nucleic acid segments that encode such pan DR binding peptides, which are useful for enhancing the immune response to a desired immunogen.

Claims (24)

1 . A composition for enhancing an immune response to an immunogen, said composition comprising a nucleic acid segment encoding a pan DR binding oligopeptide of less than about 50 amino acid residues,

wherein said pan DR binding oligopeptide comprises a peptide of the formula R 1 —R 2 —R 3 —R 4 —R 5 , wherein all amino acids of said peptide are L-amino acids, and wherein:

R 1 is any amino acid followed by alanine or lysine;

R 2 is selected from the group consisting of tyrosine and phenylalanine;

R 3 is 3 or 4 amino acids, wherein each amino acid is independently selected from the group consisting of alanine, isoleucine, serine and valine;

R 4 is selected from the group consisting of threonine-leucine-lysine, lysine-threonine, and tryptophan-threonine-leucine-lysine; and

R 5 consists of 2 to 4 amino acids each independently selected from the group consisting of alanine, serine, and valine, followed by any amino acid.

2 . A composition according to claim 1 , further comprising a nucleic acid segment encoding said immunogen.

3 . A composition according to claim 2 , wherein said immunogen is a CTL inducing-peptide.

4 . A composition according to claim 2 , wherein said immunogen is an antibody inducing-peptide.

5 . A composition according to claim 2 , wherein said immunogen is an HTL inducing-peptide.

6 . A composition according to claim 2 , wherein said nucleic acid segment encoding said pan DR binding oligopeptide and said nucleic acid segment encoding said immunogen are contained within one nucleic acid construct.

7 . A composition according to claim 6 , wherein said one nucleic acid construct is an expression vector.

8 . A composition according to claim 2 , wherein said nucleic acid segment encoding said pan DR binding oligopeptide and said nucleic acid segment encoding said immunogen are contained within more than one nucleic acid construct.

9 . A composition according to claim 8 , wherein at least one of said more than one nucleic acid constructs is an expression vector.

10 . The composition of claim 2 , wherein said immunogen is an antigen derived from a member of the group consisting of a pathogen, a diseased cell, a virus, a cancer cell, a fungus, a parasite and a bacterium.

11 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a composition according to claim 1 .

12 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a composition according to claim 2 .

13 . A method of enhancing an immune response to an immunogen, said method comprising introducing a composition according to claim 1 into a subject.

14 . A method of enhancing an immune response to an immunogen, said method comprising introducing a composition according to claim 2 into a subject.

15 . A method according to claim 13 , wherein the immune response is prophylactic.

16 . A method according to claim 14 , wherein the immune response is prophylactic.

17 . A method according to claim 13 , wherein the immune response is therapeutic.

18 . A method according to claim 14 ,. wherein the immune response is therapeutic.

Assignments (3)
CHANGE OF NAME Recorded Nov 13, 2012
From: PHARMEXA INC.
To: EPIMMUNE INC.
Reel/Frame 029291/0578 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2006
From: IDM PHARMA, INC.
To: PHARMEXA INC.
Reel/Frame 017115/0860 →
MERGER Recorded Feb 3, 2006
From: EPIMMUNE INC.
To: IDM PHARMA, INC.
Reel/Frame 017115/0312 →